Meiwand Bedar, Andre J van Wijnen, Alexander Y Shin
{"title":"异体间充质干细胞植入 NeuraGen 神经导管兔模型的安全性。","authors":"Meiwand Bedar, Andre J van Wijnen, Alexander Y Shin","doi":"10.1089/ten.TEC.2022.0159","DOIUrl":null,"url":null,"abstract":"<p><p>Mesenchymal stem cells (MSCs) stimulate nerve and tissue regeneration and are primed for clinical translation. Application of autologous MSCs is limited by requirements for expedient harvesting procedures, proliferative expansion to increase number of cells, and reduced regenerative potential due to aging or pathological conditions. Because MSCs are immune privileged, allogeneic MSCs may serve as \"off-the-shelf\" cell-based reconstructive treatments to support nerve repair. Therefore, we examined the safety and immune response parameters of allogeneic MSCs seeded on NeuraGen<sup>®</sup> Nerve Guides (NNGs) in a rabbit model. NNGs with or without allogeneic rabbit MSCs were applied to rabbit sciatic nerves. Randomly assigned treatment included group I (no surgery control, <i>n</i> = 3) or groups II and III (sciatic nerve wrapped with unseeded or allogeneic MSC-seeded NNGs; <i>n</i> = 5/group). Rabbits were euthanized after 2 weeks to monitor functional recovery by histological evaluation of sciatic nerves and tibialis anterior (TA) muscle. Host reactions to allogeneic MSCs were analyzed by assessment of body and tissue weight, temperature, as well as hematological parameters, including white blood cell count (WBC), spleen histology, and CD4<sup>+</sup> and CD8<sup>+</sup> T lymphocytes. Histological analyses of nerves and spleen were all unremarkable, consistent with absence of overt systemic and local immune responses upon allogeneic MSC administration. No significant differences were observed in WBC or CD4<sup>+</sup> and CD8<sup>+</sup> T lymphocytes across unseeded and seeded treatment groups. Thus, allogenic MSCs are safe for use and may be considered in lieu of autologous MSCs in translational animal studies as the basis for future clinical nerve repair strategies. Impact statement Autologous mesenchymal stem cells (MSC) have been reported to enhance nerve regeneration when used in conjunction with nerve graft substitutes. However, autologous stem cell sources delay treatment and may be susceptible to age- or disease-related dysfunctions. In this study, we investigated the safety of allogeneic MSCs and the optimal number of cells for nerve conduit delivery in a rabbit model. When compared with unseeded nerve conduits, allogeneic MSC-seeded conduits did not induce a systemic or local immune response. The findings of this study will ultimately facilitate the clinical translation of a universal donor cell-based treatment option for nerve defects.</p>","PeriodicalId":23154,"journal":{"name":"Tissue engineering. Part C, Methods","volume":"29 2","pages":"43-53"},"PeriodicalIF":2.7000,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10162580/pdf/","citationCount":"0","resultStr":"{\"title\":\"Safety of Allogeneic Mesenchymal Stem Cell Seeding of NeuraGen Nerve Guides in a Rabbit Model.\",\"authors\":\"Meiwand Bedar, Andre J van Wijnen, Alexander Y Shin\",\"doi\":\"10.1089/ten.TEC.2022.0159\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Mesenchymal stem cells (MSCs) stimulate nerve and tissue regeneration and are primed for clinical translation. Application of autologous MSCs is limited by requirements for expedient harvesting procedures, proliferative expansion to increase number of cells, and reduced regenerative potential due to aging or pathological conditions. Because MSCs are immune privileged, allogeneic MSCs may serve as \\\"off-the-shelf\\\" cell-based reconstructive treatments to support nerve repair. Therefore, we examined the safety and immune response parameters of allogeneic MSCs seeded on NeuraGen<sup>®</sup> Nerve Guides (NNGs) in a rabbit model. NNGs with or without allogeneic rabbit MSCs were applied to rabbit sciatic nerves. Randomly assigned treatment included group I (no surgery control, <i>n</i> = 3) or groups II and III (sciatic nerve wrapped with unseeded or allogeneic MSC-seeded NNGs; <i>n</i> = 5/group). Rabbits were euthanized after 2 weeks to monitor functional recovery by histological evaluation of sciatic nerves and tibialis anterior (TA) muscle. Host reactions to allogeneic MSCs were analyzed by assessment of body and tissue weight, temperature, as well as hematological parameters, including white blood cell count (WBC), spleen histology, and CD4<sup>+</sup> and CD8<sup>+</sup> T lymphocytes. Histological analyses of nerves and spleen were all unremarkable, consistent with absence of overt systemic and local immune responses upon allogeneic MSC administration. No significant differences were observed in WBC or CD4<sup>+</sup> and CD8<sup>+</sup> T lymphocytes across unseeded and seeded treatment groups. Thus, allogenic MSCs are safe for use and may be considered in lieu of autologous MSCs in translational animal studies as the basis for future clinical nerve repair strategies. Impact statement Autologous mesenchymal stem cells (MSC) have been reported to enhance nerve regeneration when used in conjunction with nerve graft substitutes. However, autologous stem cell sources delay treatment and may be susceptible to age- or disease-related dysfunctions. In this study, we investigated the safety of allogeneic MSCs and the optimal number of cells for nerve conduit delivery in a rabbit model. When compared with unseeded nerve conduits, allogeneic MSC-seeded conduits did not induce a systemic or local immune response. The findings of this study will ultimately facilitate the clinical translation of a universal donor cell-based treatment option for nerve defects.</p>\",\"PeriodicalId\":23154,\"journal\":{\"name\":\"Tissue engineering. Part C, Methods\",\"volume\":\"29 2\",\"pages\":\"43-53\"},\"PeriodicalIF\":2.7000,\"publicationDate\":\"2023-02-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10162580/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Tissue engineering. Part C, Methods\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1089/ten.TEC.2022.0159\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"CELL & TISSUE ENGINEERING\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Tissue engineering. Part C, Methods","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1089/ten.TEC.2022.0159","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CELL & TISSUE ENGINEERING","Score":null,"Total":0}
引用次数: 0
摘要
间充质干细胞(MSCs)可刺激神经和组织再生,并有望应用于临床。自体间充质干细胞的应用受到以下条件的限制:快速采集程序、增殖扩增以增加细胞数量,以及老化或病理条件导致再生潜力降低。由于间充质干细胞具有免疫特异性,异体间充质干细胞可作为 "现成的 "细胞重建疗法来支持神经修复。因此,我们在兔子模型中研究了将异体间充质干细胞播种到 NeuraGen® 神经导板(NNG)上的安全性和免疫反应参数。将含有或不含异体兔间充质干细胞的 NNGs 应用于兔坐骨神经。随机分配的治疗包括 I 组(无手术对照组,n = 3)或 II 组和 III 组(用未播种或播种了异体间充质干细胞的 NNG 包扎坐骨神经;n = 5/组)。兔子在 2 周后安乐死,通过对坐骨神经和胫骨前肌(TA)进行组织学评估来监测其功能恢复情况。通过评估体重和组织重量、体温以及血液学参数(包括白细胞计数(WBC)、脾脏组织学、CD4+和CD8+T淋巴细胞),分析宿主对异体间充质干细胞的反应。神经和脾脏的组织学分析结果均无异常,这与服用异体间充质干细胞后没有明显的全身和局部免疫反应一致。未播种组和播种组的白细胞、CD4+和CD8+ T淋巴细胞均无明显差异。因此,异体间充质干细胞的使用是安全的,可考虑在转化动物研究中替代自体间充质干细胞,作为未来临床神经修复策略的基础。影响声明 据报道,自体间充质干细胞(MSC)与神经移植替代物结合使用可促进神经再生。然而,自体干细胞来源会延误治疗,而且可能容易出现与年龄或疾病相关的功能障碍。在这项研究中,我们调查了异体间充质干细胞的安全性,以及在兔子模型中输送神经导管的最佳细胞数量。与未播种的神经导管相比,异体间充质干细胞播种的神经导管不会诱发全身或局部免疫反应。这项研究的结果将最终促进基于通用供体细胞的神经缺损治疗方案的临床转化。
Safety of Allogeneic Mesenchymal Stem Cell Seeding of NeuraGen Nerve Guides in a Rabbit Model.
Mesenchymal stem cells (MSCs) stimulate nerve and tissue regeneration and are primed for clinical translation. Application of autologous MSCs is limited by requirements for expedient harvesting procedures, proliferative expansion to increase number of cells, and reduced regenerative potential due to aging or pathological conditions. Because MSCs are immune privileged, allogeneic MSCs may serve as "off-the-shelf" cell-based reconstructive treatments to support nerve repair. Therefore, we examined the safety and immune response parameters of allogeneic MSCs seeded on NeuraGen® Nerve Guides (NNGs) in a rabbit model. NNGs with or without allogeneic rabbit MSCs were applied to rabbit sciatic nerves. Randomly assigned treatment included group I (no surgery control, n = 3) or groups II and III (sciatic nerve wrapped with unseeded or allogeneic MSC-seeded NNGs; n = 5/group). Rabbits were euthanized after 2 weeks to monitor functional recovery by histological evaluation of sciatic nerves and tibialis anterior (TA) muscle. Host reactions to allogeneic MSCs were analyzed by assessment of body and tissue weight, temperature, as well as hematological parameters, including white blood cell count (WBC), spleen histology, and CD4+ and CD8+ T lymphocytes. Histological analyses of nerves and spleen were all unremarkable, consistent with absence of overt systemic and local immune responses upon allogeneic MSC administration. No significant differences were observed in WBC or CD4+ and CD8+ T lymphocytes across unseeded and seeded treatment groups. Thus, allogenic MSCs are safe for use and may be considered in lieu of autologous MSCs in translational animal studies as the basis for future clinical nerve repair strategies. Impact statement Autologous mesenchymal stem cells (MSC) have been reported to enhance nerve regeneration when used in conjunction with nerve graft substitutes. However, autologous stem cell sources delay treatment and may be susceptible to age- or disease-related dysfunctions. In this study, we investigated the safety of allogeneic MSCs and the optimal number of cells for nerve conduit delivery in a rabbit model. When compared with unseeded nerve conduits, allogeneic MSC-seeded conduits did not induce a systemic or local immune response. The findings of this study will ultimately facilitate the clinical translation of a universal donor cell-based treatment option for nerve defects.
期刊介绍:
Tissue Engineering is the preeminent, biomedical journal advancing the field with cutting-edge research and applications that repair or regenerate portions or whole tissues. This multidisciplinary journal brings together the principles of engineering and life sciences in the creation of artificial tissues and regenerative medicine. Tissue Engineering is divided into three parts, providing a central forum for groundbreaking scientific research and developments of clinical applications from leading experts in the field that will enable the functional replacement of tissues.
Tissue Engineering Methods (Part C) presents innovative tools and assays in scaffold development, stem cells and biologically active molecules to advance the field and to support clinical translation. Part C publishes monthly.